All In Biotech

Drug Trial Radar · NCT07267481

Switching From Xiidra to TRYPTYR

Efficacy of Switching Participants Treated With Xiidra to TRYPTYR

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Apr 15, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
Southern College of OptometryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%. Hypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.

Conditions

  • Dry Eye
  • Dry Eyes Chronic
  • Dry Eye Syndromes
  • Eye Diseases

Interventions

  • acoltremon 0.003%Drug

    Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change between pre- and post-drop in unanesthetized Schirmer test score on Day 1Time frame: 1 day

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.